Chemotherapy Induced Nausea and Vomiting (CINV) - Market Insights, Epidemiology and Market Forecast- 2023

Publisher Name :
Date: 01-Apr-2017
No. of pages: 85
Price : Single User: US $ 4950  US $ 4208 Corporate User: US $ 14850  US $ 10395
This report is available at 15% Discount for Single User License and 30% Discount for Corporate Users License till 30 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Chemotherapy Induced Nausea and Vomiting (CINV)- Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market size of the Chemotherapy Induced Nausea and Vomiting (CINV) for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the Incident cases of Chemotherapy Induced Nausea and Vomiting (CINV) from 2013-2023.

Chemotherapy-induced nausea and vomiting (CINV) are both severe side effects of cancer treatment. CINV is a condition which makes a patient uncomfortable and has to be dealt properly as many patients delay their chemotherapy cycles or even refuse further treatment due to fear from future nausea and vomiting. Also, due to nausea and vomiting induced by chemotherapy, patients can't get nutrition properly and lose their energy and may become weak which may hinder the further chemotherapy cycles as patient wouldn't be physically string to bear the chemotherapy side-effects.

According to DelveInsight, the global market for Chemotherapy Induced Nausea and Vomiting (CINV) is estimated to be USD XX Million by 2023 at a CAGR of 8.32 % for the forecast period i.e., 2013-2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

The report will help in developing business strategies by understanding the trends shaping and driving the Chemotherapy Induced Nausea and Vomiting (CINV) market.

Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy Induced Nausea and Vomiting (CINV) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

To understand the future market competition in the 7MM market of Chemotherapy Induced Nausea and Vomiting (CINV) and Insightful review of the key market drivers and barriers.

To understand the regulatory scenario in major markets.

The Report also covers the detailed historical and forecasted Chemotherapy Induced Nausea and Vomiting (CINV)market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.

This report is available at 15% Discount for Single User License and 30% Discount for Corporate Users License till 30 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Chemotherapy Induced Nausea and Vomiting (CINV) - Market Insights, Epidemiology and Market Forecast- 2023

Table of Contents

Report Introduction
Chemotherapy Induced Nausea and Vomiting (CINV) Market Overview at a Glance
Global Market Size of CINV in 2016
Global Market Size of CINV in 2023
Chemotherapy Induced Nausea and Vomiting (CINV)
Overview
Types of CINV
Risk Factors
Pathophysiology of CINV
Epidemiology and Patient Population
Assumptions and Caveats
United States
Incident Cases of Chemotherapy Induced Nausea and Vomiting in United States
Europe
Germany
Incident Cases of Chemotherapy Induced Nausea and Vomiting in Germany
Italy
Incident Cases of Chemotherapy Induced Nausea and Vomiting in Italy
Spain
Incident Cases of Chemotherapy Induced Nausea and Vomiting in Spain
France
Incident Cases of Chemotherapy Induced Nausea and Vomiting in France
United Kingdom
Incident Cases of Chemotherapy Induced Nausea and Vomiting in United Kingdom
Japan
Incident Cases of Chemotherapy Induced Nausea and Vomiting in Japan
Treatment Algorithm
Emetic Risk Category of Chemotherapeutic Agents
Emetogenic potential of Intravenous anti-neoplastic agents
Emetogenic potential of oral anti-neoplastic agents
NHS Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV)
Summary of Anti-emetics prescribing
First line Anti-emetics
Second Line Anti-emetics
Standard Anti-Emetic Regimes for Haematology Oncology
MASCC/ESMO Antiemetic Guideline 2016
Acute Chemotherapy Induced Nausea and Vomiting Guidelines
Delayed Chemotherapy Induced Nausea and Vomiting Guidelines
Guidelines for Other types of CINV cases
Guidelines for CINV in Children
ASCO Guidelines for treatment of CINV
NCCN Guidelines for Chemotherapy Induced Nausea and Vomiting
High emetic risk Intravenous chemotherapy- acute and delayed emesis prevention
Moderate emetic risk Intravenous chemotherapy- acute and delayed emesis prevention
Low and minimal emetic risk Intravenous chemotherapy- acute and delayed emesis prevention
Oral chemotherapy- emesis prevention
Breakthrough treatment for CINV
Anticipatory Emesis Prevention/treatment
Marketed Drugs
List of Marketed Drugs
Generic Drugs and their Efficacy
Marketed Drugs Presence
Sustol: Heron Therapeutics
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Sustol
Product Profile
Sancuso: Kyowa Kirin Inc
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Sancuso
Product Profile
Aloxi: Helsinn Birex Pharmaceuticals Ltd.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Aloxi
Product Profile
Akynzeo: Helsinn Birex Pharmaceuticals Ltd.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Akynzeo
Product Profile
Emend: Merck Sharp and Dohme Ltd
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Emend
Product Profile
Varubi: Tesaro, Inc.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Varubi
Product Profile
Ivemend: Merck Sharp & Dohme Ltd
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Ivemend
Product Profile
Kytril: Hoffmann-La Roche
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Kytril
Product Profile
Syndros: Insys Therapeutics
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Syndros
Product Profile
Other Approved Drugs for Chemotherapy induced Nausea and Vomiting (CINV)
Zofran: Novartis
Zuplenz: Par Pharmaceutical, Inc.
Emerging Therapies
Pipeline Drugs
Pipeline Drugs Results
Cinvanti: Heron Therapeutics, Inc.
Clinical Development
Advantages & Disadvantages
Product Profile
Akynzeo(IV): Helsinn Birex Pharmaceuticals Ltd.
Advantages & Disadvantages
Product Profile
Sancuso: Kyowa Kirin Inc
Drug Description
Advantages & Disadvantages
Product Profile
Rolapitant(IV): Tesaro, Inc.
Drug Description
Advantages & Disadvantages
Product Profile
Market Size
Assumptions and Caveats
Forecasting Events
Global CINV: Country-Wise Market Analysis
United States
Europe
Japan
Market Drivers
Market Barriers
Unmet Needs
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight


List of Tables

Table 1: Incident Cases of Chemotherapy Induced Nausea and Vomiting in United States (2013-2023)
Table 2: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Germany (2013-2023)
Table 3: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Italy (2013-2023)
Table 4: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Spain (2013-2023)
Table 5: Incident Cases of Chemotherapy Induced Nausea and Vomiting in France (2013-2023)
Table 6: Incident Cases of Chemotherapy Induced Nausea and Vomiting in United Kingdom (2013-2023)
Table 7: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Japan (2013-2023)
Table 8: List of Marketed Drugs for Chemotherapy Induced Nausea and Vomiting
Table 9: Generic Drugs and their Efficacy for Chemotherapy Induced Nausea and Vomiting
Table 10: Marketed Drugs Presence for Chemotherapy Induced Nausea and Vomiting
Table 11: List of Pipeline Drugs for Chemotherapy Induced Nausea and Vomiting
Table 12: Results of Pipeline Drugs for Chemotherapy Induced Nausea and Vomiting
Table 13: Global Market Size of CINV in USD, Million (2013-2023)
Table 14: United States Market Size of CINV in USD, Million (2013-2023)
Table 15: Europe Market Size of CINV in USD, Million (2013-2023)
Table 16:JapanMarket Size of CINV in USD, Million (2013-2023)


List of Figures

Figure 1: Emetic Pathways involved in Nausea and Vomiting
Figure 2: Incident Cases of Chemotherapy Induced Nausea and Vomiting in United States (2013-2023)
Figure 3: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Germany (2013-2023)
Figure 4: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Italy (2013-2023)
Figure 5: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Spain (2013-2023)
Figure 6: Incident Cases of Chemotherapy Induced Nausea and Vomiting in France (2013-2023)
Figure 7: Incident Cases of Chemotherapy Induced Nausea and Vomiting in United Kingdom (2013-2023)
Figure 8: Incident Cases of Chemotherapy Induced Nausea and Vomiting in Japan (2013-2023)
Figure 9: Emetogenic potential of Intravenous anti-neoplastic agents
Figure 10: Emetogenic potential of oral anti-neoplastic agents
Figure 11: Summary of anti-emetic prescribing (in normal renal / hepatic function)
Figure 12: Summary of anti-emetic prescribing (in normal renal / hepatic function)
Figure 13: First Line Anti-Emetics
Figure 14: Second Line Anti-emetics
Figure 15: Standard Anti-Emetic Regimes For Haematology Oncology
Figure 16: Acute Nausea and Vomiting anti-emetics guideline overview
Figure 17: Delayed Nausea and Vomiting anti-emetics guideline overview
Figure 18: Delayed Nausea and Vomiting anti-emetics guideline overview
Figure 19: High emetic risk, Intravenous chemotherapy- acute and delayed emesis prevention
Figure 20: Moderate emetic risk, Intravenous chemotherapy- acute and delayed emesis prevention
Figure 21: Low and minimal emetic risk, Intravenous chemotherapy- emesis prevention
Figure 22: Oral chemotherapy- emesis prevention
Figure 23: Breakthrough treatment for CINV
Figure 24: Anticipatory Emesis Prevention/Treatment
Figure 25: Global Market Size of CINV in USD, Million (2013-2023)
Figure 26: United States Market Size of CINV in USD, Million (2013-2023)
Figure 27: Europe Market Size of CINV in USD, Million (2013-2023)
Figure 28:Japan Market Size of CINV in USD, Million (2013-2023)
  • Global Head and Neck Cancer Treatment Market 2017-2021
    Published: 14-Jun-2017        Price: US 3500 Onwards        Pages: 79
    Head and neck cancer usually starts in the squamous cells that lines the moist, mucosal surface present inside the head and neck. This type of cancer is further categorized by the affected areas such as oral cavity cancer, laryngeal cancer, pharyngeal cancer and other head and neck cancer. Other head and neck cancer includes salivary gland cancer, nasal cavity, and paranasal sinuses cancer. The analysts forecast global head & neck cancer treatment market to grow at a CAGR of 8.07%......
  • Anaplastic Oligoastrocytoma - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 71
    Anaplastic Oligoastrocytoma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Oligoastrocytoma - Pipeline Review, H1 2017, provides an overview of the Anaplastic Oligoastrocytoma (Oncology) pipeline landscape. Anaplastic oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to for......
  • Gliosarcoma - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 187
    Gliosarcoma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Pipeline Review, H1 2017, provides an overview of the Gliosarcoma (Oncology) pipeline landscape. Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting,......
  • Pontine Glioma - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 148
    Pontine Glioma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H1 2017, provides an overview of the Pontine Glioma (Oncology) pipeline landscape. Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons porti......
  • Meningioma - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 71
    Meningioma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H1 2017, provides an overview of the Meningioma (Oncology) pipeline landscape. A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid and pia mater. Most meningiom......
  • Neuroblastoma - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 417
    Neuroblastoma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H1 2017, provides an overview of the Neuroblastoma (Oncology) pipeline landscape. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further sprea......
  • Gallbladder Cancer - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 118
    Gallbladder Cancer - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H1 2017, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape. Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss.......
  • Hepatocellular Carcinoma - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2500 Onwards        Pages: 1014
    Hepatocellular Carcinoma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2017, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape. Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. S......
  • Cervical Cancer - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 575
    Cervical Cancer - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H1 2017, provides an overview of the Cervical Cancer (Oncology) pipeline landscape. Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause sy......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs